FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor MicroenvironmentDavid A. Knorr, Jeffrey V. Ravetch, Lucas Blanchard et al.|Cancer Immunology Research|2023Cited by 32
480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12Shawn M. Jensen, Bernard A. Fox, Christopher G. Twitty et al.|Regular and Young Investigator Award Abstracts|2020Cited by 5
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trialRom S. Leidner, Bernard A. Fox, Christopher Paustian et al.|Cancer Research|2024Cited by 3
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesDavid A. Knorr, Jeffrey V. Ravetch, Shawn M. Jensen et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2
148 Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccineRyan Meng, Bernard A. Fox, Tarsem Moudgil et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1